STOK - CIK 0001623526
Stoke Therapeutics, Inc. trades as STOK and has a market capitalization of $1.79 B, making it the #2180 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $184.42M, up 404.5% from the prior year and net income of -$6.88M. This page tracks Stoke Therapeutics, Inc. through 588 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -814.7% to -3.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of Dravet syndrome –
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $39.00 per share. The net proceeds from the offering were approximately $105.1 million , after deducting underwriting discounts and commissions and estimated offering expenses.
J.P. Morgan Securities LLC, Cowen and Company, LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. Canaccord Genuity LLC acted as lead manager.
The largest companies sharing Stoke Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Stoke Therapeutics, Inc. (STOK) has a market capitalization of $1.79 B as of 2026-06-10, ranking #2180 among US-listed companies.
Stoke Therapeutics, Inc. reported revenue of $184.42M for fiscal year 2025, an increase of 404.5% year over year.
In its latest fiscal year Stoke Therapeutics, Inc. reported a net loss of $6.88M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.